Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05555862 · ClinicalTrials.gov registry record · Phase 2
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL
A Phase 2 study of HPV Infection and Anal Dysplasia, sponsored by Frantz Viral Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT05555862: Active Phase 2 study of HPV Infection and Anal Dysplasia, sponsored by Frantz Viral Therapeutics.
NCT05555862 is a Phase 2 study of HPV Infection and Anal Dysplasia that is active but no longer recruiting, run by Frantz Viral Therapeutics. The registered enrollment target is 17 participants, below the 235-participant average among 13 other HPV Infection trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05555862, a Phase 2 study of HPV Infection and Anal Dysplasia, is active but no longer recruiting, sponsored by Frantz Viral Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase II double blind, placebo-controlled, randomized study of Artesunate suppositories for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
Primary Outcome
Number of participants who achieve complete or partial response after 4 5-day cycles of artesunate as determined by HRA-directed biopsy(ies)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Artesunate
Study Locations (2)
Illinois
- Anal Dysplasia Clinic MidWest - Chicago
New York
- Laser Surgery Care - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-02-10 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT05555862 still lists
NCT05555862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 235-participant average among 13 other HPV Infection trials with a reported enrollment target (93% lower).
The record links to 6 conditions, with HPV Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05555862 reports a single indexed study location in Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT05555862 about?
NCT05555862 is a clinical study titled "Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL". This is a phase II double blind, placebo-controlled, randomized study of Artesunate suppositories for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
What is the current status of trial NCT05555862?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2023-02-10. Estimated completion is 2026-12-31.
What conditions does trial NCT05555862 study?
This clinical trial studies the following conditions: HPV Infection, Anal Dysplasia, Anal High-grade Squamous Intraepithelial Lesion, HPV Disease, Anal Precancerous Condition.
What interventions are being tested in trial NCT05555862?
The interventions under investigation include: Placebo (DRUG), Artesunate (DRUG).
Who is sponsoring clinical trial NCT05555862?
This trial is sponsored by Frantz Viral Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05555862 being conducted?
This trial has 2 study locations across Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05555862's enrollment target sits among peer trials
17 14th of 13 the lowest of 13 other HPV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HPV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
RECRUITING · Phase 2
-
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
RECRUITING · Phase 2
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
PCOM2 - The Physician Communication Intervention, Version 2.0
RECRUITING · NA
-
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
RECRUITING · Phase 4
-
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI